FOLD - Amicus Therapeutics Inc Stock Price, Fair Value and News

10.74USD+0.13 (+1.23%)Delayed as of 22 Apr 2024, 12:03 pm ET

Market Summary

USD10.74+0.13

Delayedas of 22 Apr 2024, 12:03 pm

1.23%

FOLD Alerts

1 major insider sales recently.

FOLD Stock Price

View Fullscreen

FOLD RSI Chart

FOLD Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-20.68

Price/Sales (Trailing)

7.85

EV/EBITDA

-35.57

Price/Free Cashflow

-40.95

FOLD Price/Sales (Trailing)

FOLD Profitability

EBT Margin

-37.59%

Return on Equity

-94.64%

Return on Assets

-19.49%

Free Cashflow Yield

-2.44%

FOLD Fundamentals

FOLD Revenue

Revenue (TTM)

399.4M

Rev. Growth (Yr)

30.63%

Rev. Growth (Qtr)

11.19%

FOLD Earnings

Earnings (TTM)

-151.6M

Earnings Growth (Yr)

39.42%

Earnings Growth (Qtr)

-56.85%

Breaking Down FOLD Revenue

52 Week Range

10.5514.10

(Low)(High)

Last 7 days

-0.6%

Last 30 days

-11.5%

Last 90 days

-11.7%

Trailing 12 Months

-7.6%

How does FOLD drawdown profile look like?

FOLD Financial Health

Current Ratio

2.88

Debt/Equity

2.42

Debt/Cashflow

-0.18

FOLD Investor Care

Shares Dilution (1Y)

4.48%

Diluted EPS (TTM)

-0.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	336.8M	350.6M	372.4M	399.4M
2022	317.8M	321.1M	323.3M	329.2M
2021	266.8M	281.8M	293.9M	305.5M
2020	208.7M	226.9M	245.6M	260.9M
2019	108.6M	131.4M	159.6M	182.2M
2018	49.5M	63.6M	73.3M	91.2M
2017	9.1M	16.3M	25.0M	36.9M
2016	0	0	2.9M	5.3M
2014	11.5M	8.1M	4.7M	1.2M
2013	0	0	0	15.0M
2012	23.2M	29.8M	24.0M	18.4M
2011	47.2M	38.6M	30.0M	21.4M
2010	0	0	0	55.8M
2009	0	0	0	64.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amicus Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	prout samantha	sold (taxes)	-74,907	10.66	-7,027	chief accounting officer
Apr 01, 2024	campbell bradley l	acquired	64,575	8.61	7,500	president and ceo
Apr 01, 2024	campbell bradley l	sold	-87,495	11.6661	-7,500	president and ceo
Mar 15, 2024	campbell bradley l	sold (taxes)	-153,545	11.48	-13,375	president and ceo
Mar 07, 2024	sblendorio glenn	acquired	42,000	2.8	15,000	-
Mar 05, 2024	mcglynn margaret g	acquired	21,000	2.8	7,500	-
Mar 05, 2024	mcglynn margaret g	sold	-100,500	13.4	-7,500	-
Mar 05, 2024	raab michael	acquired	42,000	2.8	15,000	-
Mar 04, 2024	mcglynn margaret g	sold	-99,675	13.29	-7,500	-
Mar 04, 2024	mcglynn margaret g	acquired	21,000	2.8	7,500	-

Which funds bought or sold FOLD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-67.35	-544,255	202,380	-%
Apr 18, 2024	Park Place Capital Corp	unchanged	-	-147	719	-%
Apr 18, 2024	Diversified Trust Co	added	6.28	-104,706	784,936	0.02%
Apr 17, 2024	GRIMES & COMPANY, INC.	reduced	-0.6	-60,435	285,347	0.01%
Apr 16, 2024	CALTON & ASSOCIATES, INC.	sold off	-100	-142,060	-	-%
Apr 15, 2024	Legato Capital Management LLC	unchanged	-	-25,425	124,279	0.01%
Apr 12, 2024	DNB Asset Management AS	added	8.79	-34,691	317,732	-%
Apr 10, 2024	PARK AVENUE SECURITIES LLC	added	5.39	-22,000	155,000	-%
Apr 10, 2024	Fulton Bank, N.A.	reduced	-10.25	-41,350	120,827	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	added	37.18	153	1,260	-%

Are Funds Buying or Selling FOLD?

Are funds buying FOLD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FOLD

No. of Funds

FOLD Alerts

1 major insider sales recently.

Unveiling Amicus Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perceptive advisors llc	9.6%	28,057,456	SC 13G/A
Feb 14, 2024	redmile group, llc	7.3%	21,957,926	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	9.3%	27,400,000	SC 13G/A
Feb 13, 2024	vanguard group inc	9.72%	28,492,486	SC 13G/A
Feb 08, 2024	wellington management group llp	5.18%	15,190,024	SC 13G
Jan 26, 2024	blackrock inc.	7.8%	22,985,442	SC 13G/A
Jan 08, 2024	jpmorgan chase & co	5.9%	17,502,680	SC 13G
Dec 08, 2023	morgan stanley	4.2%	12,303,701	SC 13G/A
Feb 14, 2023	avoro capital advisors llc	9.5%	26,800,000	SC 13G/A
Feb 14, 2023	redmile group, llc	9.9%	28,599,494	SC 13G/A

Recent SEC filings of Amicus Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	4/A	Insider Trading
Mar 15, 2024	4/A	Insider Trading
Mar 15, 2024	4/A	Insider Trading
Mar 15, 2024	4/A	Insider Trading

Peers (Alternatives to Amicus Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Amicus Therapeutics Inc News

Latest updates

Amicus Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	11.2%	115,082,000	103,501,000	94,503,000	86,270,000	88,096,000	81,691,000	80,731,000	78,715,000	82,154,000	79,545,000	77,413,000	66,402,000	70,571,000	67,437,000	62,353,000	60,525,000	55,293,000	48,768,000	44,130,000	34,046,000	32,644,000
Gross Profit	10.9%	103,758,000	93,555,000	85,389,000	79,328,000	78,712,000	68,255,000	72,534,000	71,133,000	74,303,000	67,849,000	69,033,000	59,863,000	61,154,000	59,038,000	55,677,000	53,973,000	48,348,000	43,172,000	38,763,000	29,991,000	28,300,000
Operating Expenses	-2.8%	107,450,000	110,578,000	104,249,000	116,964,000	121,040,000	102,095,000	133,147,000	146,472,000	146,449,000	110,248,000	107,867,000	112,918,000	125,989,000	111,799,000	107,022,000	132,030,000	137,371,000	100,477,000	115,193,000	111,270,000	97,783,000
S&GA Expenses	7.0%	70,239,000	65,651,000	65,423,000	73,957,000	54,274,000	47,272,000	53,379,000	58,116,000	57,601,000	46,107,000	42,276,000	46,726,000	43,685,000	37,850,000	34,657,000	40,215,000	43,300,000	39,680,000	42,578,000	44,303,000	38,765,000
EBITDA Margin	35.5%	-0.23	-0.36	-0.40	-0.50	-0.61	-0.66	-0.73	-0.69	-0.66	-0.66	-0.74	-0.80	-	-	-	-	-	-	-	-	-
Interest Expenses	-1.2%	12,827,000	12,986,000	12,492,000	11,844,000	11,095,000	9,620,000	8,257,000	8,147,000	8,164,000	8,165,000	8,150,000	7,992,000	8,277,000	6,784,000	3,635,000	3,729,000	3,767,000	4,026,000	4,625,000	6,454,000	8,639,000
Income Taxes	169.8%	2,183,000	-3,128,000	2,715,000	-287,000	-14,214,000	4,023,000	911,000	3,809,000	2,981,000	-182,000	4,525,000	1,582,000	-2,193,000	727,000	3,703,000	361,000	-156,000	-251,000	717,000	168,000	1,010,000
Earnings Before Taxes	-28.2%	-31,660,000	-24,705,000	-40,517,000	-53,219,000	-70,079,000	-29,263,000	-61,246,000	-81,451,000	-80,296,000	-50,476,000	-46,700,000	-64,082,000	-73,594,000	-63,284,000	-48,789,000	-88,587,000	-89,885,000	-62,060,000	-83,834,000	-120,131,000	-77,072,000
EBT Margin	25.8%	-0.38	-0.51	-0.55	-0.63	-0.74	-0.78	-0.85	-0.81	-0.79	-0.80	-0.88	-0.94	-	-	-	-	-	-	-	-	-
Net Income	-56.8%	-33,843,000	-21,577,000	-43,232,000	-52,932,000	-55,865,000	-33,286,000	-62,157,000	-85,260,000	-83,277,000	-50,294,000	-51,225,000	-65,664,000	-71,401,000	-64,011,000	-52,492,000	-88,948,000	-89,729,000	-61,809,000	-84,551,000	-120,299,000	-78,083,000
Net Income Margin	18.6%	-0.38	-0.47	-0.53	-0.61	-0.72	-0.82	-0.87	-0.85	-0.82	-0.81	-0.90	-0.95	-	-	-	-	-	-	-	-	-
Free Cashflow	104.3%	1,727,000	-39,912,000	-18,335,000	-20,011,000	-83,449,000	-11,489,000	-16,217,000	-59,186,000	-72,274,000	-24,590,000	-36,289,000	-73,222,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.8%	778	764	730	701	724	760	801	827	905	957	787	810	887	901	701	738	850	882	918	765	790
Current Assets	4.3%	483	463	433	400	424	459	498	519	597	651	481	503	579	585	384	408	520	577	635	483	551
Cash Equivalents	-6.2%	247	263	211	161	149	278	236	233	245	386	177	185	166	211	165	123	146	166	221	96.00	82.00
Inventory	4.8%	60.00	57.00	51.00	27.00	24.00	13.00	21.00	24.00	27.00	22.00	24.00	19.00	20.00	16.00	13.00	13.00	14.00	9.00	10.00	8.00	8.00
Net PPE	1.9%	32.00	31.00	30.00	31.00	31.00	32.00	34.00	35.00	42.00	42.00	42.00	43.00	44.00	45.00	47.00	48.00	48.00	35.00	15.00	13.00	11.00
Goodwill	0%	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198
Liabilities	-2.1%	618	631	619	598	601	627	627	588	598	580	573	559	600	580	340	336	374	334	318	313	447
Current Liabilities	-1.0%	168	169	159	138	139	165	165	130	146	121	112	100	130	112	108	92.00	129	93.00	90.00	66.00	86.00
Long Term Debt	-1.6%	388	394	393	393	392	391	391	390	389	389	390	390	389	389	-	-	150	-	-	-	-
Shareholder's Equity	20.2%	160	133	112	103	123	133	173	239	307	377	214	251	286	320	361	403	476	548	600	452	343
Retained Earnings	0%	-2,700	-2,700	-2,628	-2,585	-2,532	-2,500	-2,443	-2,381	-2,295	-2,212	-2,162	-2,100	-2,045	-1,974	-1,910	-1,900	-1,768	-1,678	-1,600	-1,532	-1,412
Additional Paid-In Capital	1.7%	2,836	2,787	2,733	2,692	2,665	2,645	2,631	2,618	2,595	2,580	2,364	2,351	2,309	2,275	2,251	2,238	2,227	2,211	2,201	1,971	1,740
Accumulated Depreciation	1.6%	25.00	25.00	24.00	23.00	22.00	23.00	22.00	21.00	20.00	19.00	17.00	16.00	14.00	24.00	21.00	19.00	18.00	18.00	17.00	16.00	16.00
Shares Outstanding	1.0%	294	291	287	283	281	289	292	288	271	266	265	264	-	-	-	-	-	-	-	-	-
Float	-	-	-	3,557	-	-	-	2,980	-	-	-	2,541	-	-	-	3,851	-	-	-	3,147	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	109.0%	3,458	-38,347	-16,133	-18,069	-80,772	-11,626	-15,862	-58,315	-70,514	-23,700	-35,923	-72,354	-49,822	-42,008	-33,518	-107,942	-57,832	-55,553	-58,485	-78,546	-60,677
Share Based Compensation	9.6%	18,095	16,511	16,577	34,894	18,626	14,772	12,463	30,651	13,907	11,841	11,736	20,354	12,239	15,908	8,408	12,596	12,908	8,843	9,935	12,744	8,387
Cashflow From Investing	-167.0%	-23,957	35,765	50,001	36,255	-66,704	74,515	26,292	58,213	-68,089	34,572	25,713	86,565	-22,776	-154,061	70,012	93,246	26,963	3,193	-15,068	80,065	-63,801
Cashflow From Financing	-78.2%	8,210	37,619	23,673	-7,825	557	-559	693	-8,154	-104	201,113	2,235	8,829	21,548	238,711	4,086	-1,487	3,191	523	196,404	17,384	359

FOLD Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net product sales	$ 399,356	$ 329,233	$ 305,514
Cost of goods sold	37,326	38,599	34,466
Gross profit	362,030	290,634	271,048
Operating expenses:
Research and development	152,381	276,677	272,049
Selling, general, and administrative	275,270	213,041	192,710
Changes in fair value of contingent consideration payable	2,583	1,078	6,514
Loss on impairment of assets	1,134	6,616	0
Depreciation and amortization	7,873	5,342	6,209
Total operating expenses	439,241	502,754	477,482
Loss from operations	(77,211)	(212,120)	(206,434)
Other (expense) income:
Interest income	7,078	3,024	509
Interest expense	(50,149)	(37,119)	(32,471)
Loss on extinguishment of debt	(13,933)	0	(257)
Other (expense) income	(15,886)	4,176	(2,901)
Loss before income tax	(150,101)	(242,039)	(241,554)
Income tax (expense) benefit	(1,483)	5,471	(8,906)
Net loss attributable to common stockholders	$ (151,584)	$ (236,568)	$ (250,460)
Net loss attributable to common stockholders per common share - basic (in dollars per share)	$ (0.51)	$ (0.82)	$ (0.92)
Net loss attributable to common stockholders per common share - diluted (in dollars per share)	$ (0.51)	$ (0.82)	$ (0.92)
Weighted-average common shares outstanding - basic (in shares)	295,164,515	289,057,198	271,421,986
Weighted-average common shares outstanding - diluted (in shares)	295,164,515	289,057,198	271,421,986

FOLD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 246,994	$ 148,813
Investments in marketable securities	39,206	144,782
Accounts receivable	87,632	66,196
Inventories	59,696	23,816
Prepaid expenses and other current assets	49,533	40,209
Total current assets	483,061	423,816
Operating lease right-of-use assets, net	26,312	29,534
Property and equipment, less accumulated depreciation of $25,429 and $22,281 at December 31, 2023 and 2022, respectively	31,667	30,778
Intangible assets, less accumulated amortization of $2,510 and $0 at December 31, 2023 and December 31, 2022, respectively	20,490	23,000
Goodwill	197,797	197,797
Other non-current assets	18,553	19,242
Total Assets	777,880	724,167
Current liabilities:
Accounts payable	15,120	15,413
Accrued expenses and other current liabilities	144,245	93,636
Contingent consideration payable	0	21,417
Operating lease liabilities	8,324	8,552
Total current liabilities	167,689	139,018
Long-term debt	387,858	391,990
Operating lease liabilities	48,877	51,578
Other non-current liabilities	13,282	18,534
Total liabilities	617,706	601,120
Commitments and contingencies
Stockholders' equity:
Common stock, $0.01 par value, 500,000,000 shares authorized, 293,594,209 and 281,108,273 shares issued and outstanding at December 31, 2023 and 2022, respectively	2,918	2,815
Additional paid-in capital	2,836,018	2,664,744
Accumulated other comprehensive gain (loss):
Foreign currency translation adjustment	5,429	(11,989)
Unrealized loss on available-for-sale securities	(188)	(116)
Warrants	71	83
Accumulated deficit	(2,684,074)	(2,532,490)
Total stockholders' equity	160,174	123,047
Total Liabilities and Stockholders' Equity	$ 777,880	$ 724,167

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

CEO	Mr. Bradley L. Campbell M.B.A.
WEBSITE	https://amicusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	484

Amicus Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Amicus Therapeutics Inc? What does FOLD stand for in stocks?

FOLD is the stock ticker symbol of Amicus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amicus Therapeutics Inc (FOLD)?

As of Fri Apr 19 2024, market cap of Amicus Therapeutics Inc is 3.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FOLD stock?

You can check FOLD's fair value in chart for subscribers.

What is the fair value of FOLD stock?

You can check FOLD's fair value in chart for subscribers. The fair value of Amicus Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amicus Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FOLD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amicus Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FOLD is over valued or under valued. Whether Amicus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Amicus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FOLD.

What is Amicus Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, FOLD's PE ratio (Price to Earnings) is -20.68 and Price to Sales (PS) ratio is 7.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FOLD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amicus Therapeutics Inc's stock?

In the past 10 years, Amicus Therapeutics Inc has provided 0.189 (multiply by 100 for percentage) rate of return.